Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.

Avera McKennan Hospital & University Health Center1 site in 1 country130 target enrollmentJune 2012

ConditionsPharmacogenomics and Cardiovascular Events

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pharmacogenomics and Cardiovascular Events
Sponsor: Avera McKennan Hospital & University Health Center
Enrollment: 130
Locations: 1
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.

Detailed Description

The objective of this project is to distinguish genetic profiles that will assist a practitioner in determining the right dose or alternate medication for the patient. In partnership with the genetics team of the Avera Institute for Human Genetics and physicians with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research team will perform genetic analysis to identify genetic variances.

Registry

clinicaltrials.gov

Start Date

June 2012

End Date

January 2015

Last Updated

10 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Avera McKennan Hospital & University Health Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Currently taking or prescribed Clopidogrel or under consideration
•Acute/interventionPatients of the Avera Heart Hospital
•Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute